Skip to main content
Dartmouth-Hitchcock logo
Summer Flowers In This Section
A Long-Term, Open-Label Extension Study Of Tofacitinib (Cp-690,550) For The Treatment Of Psoriatic Arthritis (A3921092)
Principal Investigator (?)
Study Number
This is a Phase 3, long-term open-label extension study to evaluate the safety, tolerability and efficacy of tofacitinib in subjects with active PsA who have previously participated in randomized studies of tofacitinib for this indication. This study will include a sub-study to evaluate the efficacy, safety and tolerability of tofacitinib 5 mg BID administered as monotherapy after methotrexate withdrawal compared to tofacitinib 5 mg BID continued in combination with methotrexate. The sub-study will be available to subjects who have completed at least 24 months of participation in the open-label extension study and meet eligibility criteria for the sub-study. 
Phase (?)
Phase III
Sponsor (?)

Jill Brooker

Available at the following location(s)


View more details from